Human blood plasma is the starting material for a surprisingly wide range of medicines, from antibody therapies that protect people with immune deficiencies to clotting factors that stop life-threatening bleeds in hemophilia. The core manufacturing process breaks plasma down into its protein components through a technique called fractionation, which has been in use since the 1940s and still forms the backbone of production today. The resulting products treat conditions spanning intensive care, rare genetic diseases, surgical bleeding, and autoimmune disorders. Some are irreplaceable because the proteins they contain are too complex to manufacture synthetically, making donated plasma one of the few raw materials in medicine that no factory can fully replicate.
How Plasma Becomes Medicine
Plasma is the straw-colored liquid portion of blood, roughly 90 percent water plus hundreds of dissolved proteins. Turning it into medicines relies on cold ethanol fractionation, a method developed in the 1940s that works on a principle similar to refining crude oil: you progressively separate out different protein groups by adjusting temperature, alcohol concentration, and acidity. This approach remains the most widely used industrial method, though manufacturers now combine it with chromatographic purification steps to improve the purity and yield of individual proteins.1PubMed Central. Implementation of Plasma Fractionation in Biological Medicines Production Modern fractionation facilities have also expanded the number of proteins they can isolate from a single pool of plasma, including alpha-1 protease inhibitor, von Willebrand factor, and protein C, meaning a single donation can yield multiple therapies.
Before any of these products reach patients, the plasma goes through rigorous pathogen-reduction steps. The HIV and hepatitis crises of the 1980s drove the industry to adopt layered safety measures. Today, virtually all plasma-derived medicines undergo solvent-detergent treatment to inactivate enveloped viruses, heat treatment, and nanofiltration, which pushes the protein solution through membranes with pore sizes as small as 15 to 40 nanometers, physically trapping virus particles.2PubMed. Nanofiltration of plasma-derived biopharmaceutical products Two decades of large-scale experience have confirmed nanofiltration as a robust viral-removal technique, with filter pore size and virus size being the main factors determining how effectively a given pathogen is caught.3PubMed Central. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years’ experience of the plasma protein manufacturers These overlapping steps have made modern plasma products far safer than earlier generations.
Immunoglobulin Therapies
Immunoglobulin, or antibody concentrate, is the single largest category of plasma-derived medicine by volume and by revenue. It is given either intravenously (IVIG) or subcutaneously (SCIG) and serves two broad purposes: replacing missing antibodies in people whose immune systems cannot make enough, and modulating an overactive immune response in autoimmune and inflammatory conditions.
For patients with primary immunodeficiencies, regular immunoglobulin infusions are the standard of care. These include conditions like common variable immunodeficiency, X-linked agammaglobulinaemia, severe combined immunodeficiency, and Wiskott-Aldrich syndrome.4PubMed Central. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy The infused antibodies fill the gap left by the patient’s defective immune system, dramatically lowering the rate of serious bacterial infections. Evidence shows that keeping antibody trough levels high enough can prevent not only acute infections but also chronic lung damage and autoimmune complications over the long term.5Frontiers in Pediatrics. Immunoglobulin replacement therapies in inborn errors of immunity: a review In clinical trials, patients on IVIG experienced very low rates of serious bacterial infection and missed only a couple of days of work or school per year because of illness, with the infused IgG lasting roughly 30 days in circulation.6PubMed Central. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency
On the immunomodulatory side, IVIG is used in neurological conditions like Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), where the immune system attacks the body’s own nerves. IVIG is a first-line treatment for both, though a meaningful fraction of patients do not respond fully to it or to any of the available broad-spectrum immune therapies.7PubMed Central. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP Higher-dose immunoglobulin is also prescribed for Kawasaki disease, immune thrombocytopenia, and certain autoimmune cytopenias. Because IVIG pools antibodies from thousands of donors, it contains a broad spectrum of specificities that collectively dampen pathological immune activity through mechanisms researchers are still working to fully characterize.
Clotting Factor Concentrates
Plasma-derived clotting factors were among the earliest products to emerge from fractionation technology. The breakthrough came in the 1960s when researchers discovered that slowly thawing frozen plasma at refrigerator temperature produced a concentrated precipitate rich in factor VIII, the protein missing in hemophilia A. That discovery made specific treatment for hemophilia possible for the first time.
Today, plasma-derived concentrates supply factor VIII for hemophilia A, factor IX for hemophilia B, and von Willebrand factor for von Willebrand disease. In wealthier countries, recombinant (lab-manufactured) clotting factors have largely replaced plasma-derived ones for hemophilia A and B. But for most of the world’s hemophilia population, plasma-derived products remain the backbone of treatment because recombinant alternatives are far more expensive.8PubMed. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease For von Willebrand disease specifically, plasma-derived concentrates containing both von Willebrand factor and factor VIII remain a primary treatment option regardless of a country’s income level, since recombinant von Willebrand factor is newer and less widely available.
An ongoing clinical question is whether plasma-derived or recombinant factor VIII is better for patients who have never been treated before. The SIPPET randomized trial found that patients receiving recombinant factor VIII developed inhibitors, a serious immune complication that makes the treatment stop working, at a higher rate than those receiving plasma-derived products.9Frontiers in Immunology. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products That finding has not settled the debate, since recombinant products offer certain manufacturing advantages, but it has kept plasma-derived clotting factors squarely relevant even in well-resourced healthcare systems.
Human Serum Albumin
Albumin is the most abundant protein in plasma and one of the oldest plasma-derived products, first used during World War II for battlefield resuscitation. It is still manufactured at large scale and used primarily in critical care and liver disease. Albumin expands blood volume, transports drugs and hormones, and has antioxidant and anti-inflammatory properties that go beyond simple volume replacement.
The most established uses are in patients with advanced liver cirrhosis. Albumin combined with vasoconstrictors improves kidney function and survival in hepatorenal syndrome. In spontaneous bacterial peritonitis, albumin lowers the risk of kidney injury and death, particularly in high-risk cirrhotic patients. And after large-volume paracentesis (draining fluid from the abdomen), albumin infusions reduce the circulatory instability that can follow.10PubMed Central. Use of Human Serum Albumin in Critically Ill Patients: A Narrative Review These indications are well supported, and albumin treatment in each of them has been linked to improved survival.11PubMed. Human serum albumin, systemic inflammation, and cirrhosis
That said, the evidence is less encouraging for using albumin as a general-purpose strategy in hospitalized cirrhosis patients. A large randomized trial tested whether aggressively infusing albumin to reach a specific blood-level target would reduce infections, kidney dysfunction, and death. It did not. Outcomes were no better in the group receiving targeted albumin infusions than in the standard-care group, and the albumin group actually experienced more severe adverse events.12PubMed. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis The takeaway is that albumin works well for specific, well-defined scenarios in liver disease but is not a blanket solution just because a patient’s albumin level is low. Similarly, in septic shock, trials have generally shown no overall mortality benefit from albumin compared with cheaper crystalloid fluids, though albumin may help with blood pressure support in certain subgroups.10PubMed Central. Use of Human Serum Albumin in Critically Ill Patients: A Narrative Review
Hyperimmune Globulins
While standard immunoglobulin pools antibodies from thousands of general donors, hyperimmune globulins are made from the plasma of donors with high levels of a specific antibody. The result is a concentrated dose of targeted protection against a particular pathogen or antigen.
The best-known example is anti-D immunoglobulin (Rh immunoglobulin), given to Rh-negative mothers who carry an Rh-positive baby. Without treatment, the mother’s immune system can develop antibodies against the baby’s red blood cells, causing hemolytic disease in future pregnancies. Anti-D given within 72 hours of delivery slashes that risk dramatically, reducing the rate of Rh sensitization at six months after birth by roughly 96 percent and lowering the risk of problems in the next pregnancy by about 88 percent.13Cochrane Database of Systematic Reviews. Anti‐D administration after childbirth for preventing Rhesus alloimmunisation Anti-D was developed in the 1960s alongside clotting factor concentrates and has been one of the great public health successes of plasma medicine.
Other hyperimmune products include hepatitis B immunoglobulin (given after needlestick injuries or to newborns of infected mothers), tetanus immunoglobulin (for wound prophylaxis when vaccination status is uncertain), rabies immunoglobulin (administered alongside the vaccine after an animal bite), and varicella-zoster immunoglobulin (for immunocompromised individuals exposed to chickenpox). Each is manufactured from donors screened for high titers of the relevant antibody.
Alpha-1 Antitrypsin Augmentation
Alpha-1 antitrypsin (AAT) deficiency is a genetic condition in which the liver produces too little of a protein that protects the lungs from inflammatory damage. Without enough AAT, an enzyme called neutrophil elastase gradually destroys lung tissue, leading to early-onset emphysema. The specific treatment is augmentation therapy: weekly intravenous infusions of AAT purified from pooled human plasma.
Augmentation therapy raises AAT levels in the blood and in the fluid lining the lungs, restoring the anti-elastase shield and reducing inflammatory markers.14PubMed Central. Diagnosis and augmentation therapy for alpha-1 antitrypsin deficiency: current knowledge and future potential Observational studies suggest it slows lung function decline, particularly in patients who still have moderate lung function, and one observational study linked it to reduced mortality in patients with moderate to severe impairment. Randomized trials using CT-scan-based measurements of lung density have confirmed that the therapy slows the loss of lung tissue over time.15PubMed Central. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
The picture is not entirely straightforward, however. A Cochrane review found that augmentation therapy may have little or no effect on overall mortality and noted it could slightly increase the rate of airway disease flare-ups, though uncertainty was high.16PubMed Central. Alpha 1 antitrypsin augmentation therapy for alpha 1 antitrypsin deficiency-associated lung disease This tension between the CT-density evidence (which favors treatment) and the clinical-outcome evidence (which is less clear) makes AAT augmentation one of those therapies where the biological rationale is compelling but the proof of hard clinical benefit remains debated. Patients and physicians typically weigh the lung-density data alongside the absence of any alternative disease-modifying treatment for this condition.
C1 Inhibitor for Hereditary Angioedema
Hereditary angioedema (HAE) is a rare genetic condition causing episodes of severe swelling in the face, throat, abdomen, and extremities. The most common form results from a deficiency of C1 esterase inhibitor, a plasma protein that regulates part of the immune complement system. Plasma-derived C1 inhibitor concentrate is considered first-line therapy both for treating acute attacks and for preventing them.17The Journal of Allergy and Clinical Immunology: In Practice. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema—A Long-Term Survey
The clinical data on this product are striking. In studies comparing C1 inhibitor concentrate to placebo for acute HAE attacks, about 69 percent of attacks treated with C1 inhibitor showed some improvement within 30 minutes, compared with just 2 percent in the placebo group. The average time from infusion to initial relief was under an hour, versus more than nine hours for placebo.18PubMed Central. Treatment of hereditary angioedema with plasma-derived C1 inhibitor For a condition in which throat swelling can become a medical emergency, that speed matters enormously. Patients on long-term preventive infusions experience fewer attacks overall, and the therapy has demonstrated a good safety profile in both adults and children.
Fibrin Sealants and Surgical Products
Not all plasma medicines are infused into the bloodstream. Fibrin sealants, also called fibrin glues, are topical products made from plasma-derived fibrinogen and thrombin that mimic the final step of the clotting cascade. When the two components are mixed at the site of a wound or surgical incision, they rapidly form a fibrin clot that seals tissue and controls bleeding.
Surgeons use fibrin sealants to seal porous vascular grafts, control bleeding from suture holes and small tears during cardiac surgery, and promote wound healing in a range of procedures from neurosurgery to skin grafting. Early clinical experience established that fibrin glue derived from single-donor plasma was as effective as products made from pooled blood in sealing grafts and stopping bleeding, with no bleeding complications at treated sites.19PubMed. Hemostatic effectiveness of fibrin glue derived from single-donor fresh frozen plasma Modern commercial fibrin sealants undergo the same viral inactivation steps as other plasma products and are available in ready-to-use formats that can be applied with dual-syringe applicators during surgery.
Convalescent Plasma and Emerging Uses
The idea of using plasma from recovered patients to treat the sick is actually more than a century old, predating any formal fractionation technology. Convalescent plasma delivers ready-made antibodies from someone who has fought off an infection to someone still battling it. The concept was revived at large scale during the COVID-19 pandemic, when convalescent plasma from recovered patients received emergency authorization as a treatment for hospitalized COVID-19 patients.20PubMed Central. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19 The approach was considered particularly valuable early in the pandemic, before vaccines or specific antiviral drugs were available.21PubMed Central. Treatment for emerging viruses: Convalescent plasma and COVID-19
Subsequent large trials tempered the early enthusiasm. Convalescent plasma showed the most benefit when given early in disease, when antibody titers in the donated plasma were high, and when recipients had not yet mounted their own immune response. For patients already on ventilators or with established organ damage, the evidence of benefit was much weaker. The experience reinforced that passive antibody therapy works best as a bridge, buying time for the patient’s own immune system or for other treatments to take hold, rather than as a rescue therapy late in the course of severe illness.
The Global Supply Problem
One persistent challenge with plasma-derived medicines is that they all depend on human donors. Unlike pills that can be synthesized in a chemical plant, these products require enormous volumes of donated plasma. The global fractionation industry is heavily dependent on source plasma collected from paid donors in the United States, which supplies a disproportionate share of the world’s plasma-derived medicines.22PubMed Central. Securing commitment and control for the supply of plasma derivatives for public health systems. I: A short review of the global landscape Many countries that rely on voluntary, unpaid blood donation simply cannot collect enough plasma to meet their domestic needs for immunoglobulin and other products.
This creates real access gaps. Immunoglobulin replacement therapy is covered by national health systems in most European countries but is inconsistently available in lower- and middle-income regions, where patients with primary immunodeficiency may go undiagnosed or untreated simply because the product is too expensive or supply is unreliable. The same pattern applies to clotting factors for hemophilia, as noted earlier, and to niche products like C1 inhibitor concentrate.
Frequent plasma donation also raises questions about donor health. A systematic review found that donating at the maximum allowed frequency of twice per week may cause a clinically meaningful drop in ferritin (the body’s iron stores) and can push immunoglobulin G levels below the lower threshold considered normal.23PubMed. Balancing Donor Health and Plasma Collection: A Systematic Review of the Impact of Plasmapheresis Frequency The evidence on this point is still considered low certainty, partly because the healthiest donors tend to keep donating while those who feel unwell drop out, which makes it harder to measure true long-term effects. Still, it has prompted discussion about whether donation frequency limits should be revisited in some countries.
How Different Countries Handle Plasma Safety
Regulatory standards for plasma collection and manufacturing vary around the world in ways that directly affect the products patients receive. The United States requires an inventory hold of at least 45 days, meaning plasma sits in quarantine before it can be used for fractionation. During that window, if a donor later tests positive for an infectious disease, the stored plasma can be pulled. China takes a stricter approach, requiring plasma to be held for at least 60 days and mandating that the donor return for a second round of negative test results before the plasma is released for manufacturing.24Annals of Blood. A holistic view of international regulations and industry standards governing collection of plasma and manufacture of plasma-derived medicinal products China also requires that companies collecting plasma and those manufacturing products from it be vertically integrated, with traceability technologies like RFID tracking donations through the system.
These differences reflect varying risk tolerances and public health histories. Countries that experienced contaminated-blood scandals tend to adopt the most stringent controls. For patients, the practical upshot is that plasma-derived medicines manufactured under any of the major regulatory frameworks are considered safe, but the specific safeguards differ enough that products cannot always move freely across borders without additional testing or certification. That fragmentation in regulation contributes to the supply bottlenecks that make these therapies hard to access in parts of the world that need them most.